Summary
BeiGene, Ltd. (ONC) reported its 2020 financial and operational highlights in its Form 10-K, showcasing significant growth in product revenue, largely driven by its internally developed medicines BRUKINSA® and tislelizumab, alongside in-licensed products. Despite a substantial increase in research and development (R&D) expenses to support its expanding pipeline and commercial operations, the company secured considerable financing, including a significant investment from Amgen and a collaboration with Novartis for tislelizumab, which provides substantial upfront and milestone payments. The company's strategy centers on advancing its innovative oncology pipeline, with a strong emphasis on its China-inclusive clinical development approach and leadership in the Chinese market. Key developments include multiple regulatory submissions and approvals in China for its lead products, indicating a robust path to market and potential for future growth in key global pharmaceutical markets.
Financial Highlights
57 data points| Revenue | $308.87M |
| Cost of Revenue | $70.66M |
| Gross Profit | $238.22M |
| R&D Expenses | $1.29B |
| SG&A Expenses | $600.18M |
| Operating Expenses | $1.97B |
| Operating Income | -$1.66B |
| Interest Expense | $18.31M |
| Net Income | -$1.63B |
| EPS (Basic) | $-1.47 |
| EPS (Diluted) | $-1.50 |
| Shares Outstanding (Basic) | 1.09B |
| Shares Outstanding (Diluted) | 1.09B |
Key Highlights
- 1Total revenues decreased by 27.9% to $308.9 million in 2020 from $428.2 million in 2019, primarily due to the absence of collaboration revenue following the termination of a BMS collaboration agreement.
- 2Product revenue increased by 38.8% to $308.9 million in 2020 from $222.6 million in 2019, driven by strong sales growth of internally developed products (BRUKINSA® and tislelizumab) and initial sales of in-licensed product XGEVA®.
- 3Research and Development (R&D) expenses increased by 39.6% to $1.3 billion in 2020 from $927.3 million in 2019, reflecting significant investments in the company's clinical pipeline, including expansion of trials for tislelizumab and BRUKINSA®.
- 4Selling, General, and Administrative (SG&A) expenses increased by 54.6% to $600.2 million in 2020 from $388.2 million in 2019, primarily due to the expansion of commercial operations and increased headcount.
- 5The company secured substantial financing, raising $2.8 billion through a collaboration with Amgen and $2.1 billion from a registered direct offering, bolstering its cash position to $1.39 billion as of December 31, 2020.
- 6Key regulatory milestones in 2020/early 2021 included the China NMPA approval for tislelizumab in first-line squamous NSCLC and for BLINCYTO® in China. Additionally, the company announced the inclusion of tislelizumab, BRUKINSA®, and XGEVA® in China's National Reimbursement Drug List (NRDL).
- 7A significant strategic collaboration was announced with Novartis for the development, manufacturing, and commercialization of tislelizumab in key global markets (North America, Japan, EU, etc.), including an upfront payment of $650 million and potential milestone payments and royalties.